BeyondSpring Inc.
BYSINasdaq
$1.29
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↓ -41.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.6M
Free Cash Flow (TTM)
-$18.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
22.2%
ROIC
—
Debt / Equity
—
Net Cash
$7.9M
Return 1Y
-41.4%
Company profile
Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.
- CEO
- Lan Huang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- New Jersey
- Website
- beyondspringpharma.com
Earnings
BYSI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $180,000.00 | $1.4M | $1.4M | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.2M | -$66.2M | -$37.2M | -$15.1M | -$8.8M | -$8.9M |
| Net income | -$61.0M | -$64.2M | -$33.3M | -$21.0M | -$11.1M | -$1.0M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$43.7M | -$47.2M | -$27.5M | -$16.5M | -$16.4M | -$19.8M |
| Free cash flow | -$43.8M | -$50.1M | -$27.5M | -$16.6M | -$16.7M | -$19.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -35672.8% | -4903.0% | -2756.4% | — | — | — |
| Net margin | -33873.9% | -4750.5% | -2463.3% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.6M | -$2.4M | -$1.7M | -$2.6M | -$1.9M | -$1.8M | -$2.6M | -$2.2M |
| Net income | -$4.0M | -$2.1M | -$1.7M | $4.5M | -$1.8M | -$1.5M | -$2.1M | -$2.2M |
| Diluted EPS | -$0.04 | — | — | — | -$0.10 | $0.16 | — | — |
| Operating cash flow | -$7.0M | -$5.2M | $982,000.00 | -$4.2M | -$5.9M | -$4.2M | -$5.5M | -$3.3M |
| Free cash flow | -$7.0M | -$5.4M | $955,000.00 | -$4.2M | -$5.9M | -$4.2M | -$5.5M | -$3.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 18, 2026
May 13, 2026
- 68d agoBeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)investorshub.advfn.com
- 68d ago12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionfinance.yahoo.com
- 68d agoBeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.